Back to dataset
The Fracture Liaison Service Database (FLS-DB) Jan to June 2016FLS-DB data definitions
You're previewing the first 4 rows of this file.
Download this file| Data field position | Column A | Column B | Column C | Column D | Column E | Column F | Column G | Column H | Column I | Column J | Column K | Column L | Column M | Column N | Column O | Column P | Column Q | Column R | Column S | Column T | Column U | Column W | Column X | Column Y | Column Z | Column AA | Column AB | Column AC | Column AD | Column AE | Column AF | Column AG | Column AI | Column AJ | Column AK | Column AL | Column AM | Column AN | Column AO | Column AP | Column AQ | Column AR | Column AS | Column AT | Column AU | Column AV | Column AW | Column AX | Column AY | Column AZ | Column BA | Column BB | Column BC | Column BD | Column BE | Column BF | Column BG | Column BH | Column BI | Column BJ | Column BK | Column BL | Column BM | Column BN | Column BO | Column BP | Column BQ | Column BS | Column BT | Column BU | Column BV | Column BW | Column BX | Column BY | Column BZ | Column CA | Column CB | Column CC | Column CD | Column CE | Column CF |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Data field | FLS Name | Number of cases submitted | Uploaded in bulk (Y/N) | Number of fields (out of 29) with 20% or more missing data | Number of fields (out of 29) with 50% or more missing data | From NHFD - Hip | From NHFD - Non-hip | From FLS-DB - Hip | From FLS-DB - Non-hip | FLS-DB case identification % - Hip | FLS-DB case identification % - Non-hip | Diagnosis to FLS assessment within 7 days (n) | Diagnosis to FLS assessment within 7 days (%) | Diagnosis to FLS assessment within 30 days (n) | Diagnosis to FLS assessment within 30 days (%) | Diagnosis to FLS assessment within 90 days (n) | Diagnosis to FLS assessment within 90 days (%) | Diagnosis to FLS assessment 91 days or more (n) | Diagnosis to FLS assessment 91 days or more (%) | Diagnosis to FLS assessment (days)Missing (n) | Diagnosis to FLS assessment (days)Missing (%) | Time to DXA scan from fracture diagnosis Within 7 days (n) | Time to DXA scan from fracture diagnosis Within 7 days (%) | Time to DXA scan from fracture diagnosis Within 30 days (n) | Time to DXA scan from fracture diagnosis Within 30 days (%) | Time to DXA scan from fracture diagnosis Within 90 days (n) | Time to DXA scan from fracture diagnosis Within 90 days (%) | Time to DXA scan from fracture diagnosis Within 91 days or more(n) | Time to DXA scan from fracture diagnosis Within 91 days or more(%) | Time to DXA scan from fracture diagnosis days missing (n) | Time to DXA scan from fracture diagnosis days missing (%) | Total DXA recommended | Q4.01 Bone therapy recommended after index fracture - Treated (oral bisphosphonates, denosumab, zolendronate) (n) | Q4.01 Bone therapy recommended after index fracture - Treated (oral bisphosphonates, denosumab, zolendronate) (%) | Q4.01 Bone therapy recommended after index fracture - Inappropriate (n) | Q4.01 Bone therapy recommended after index fracture - Inappropriate (%) | Q4.01 Bone therapy recommended after index fracture - Informed decline (n) | Q4.01 Bone therapy recommended after index fracture - Informed decline (%) | Q4.01 Bone therapy recommended after index fracture -Referred to GP to decide prescription (n) | Q4.01 Bone therapy recommended after index fracture - Referred to GP to decide prescription (%) | Q4.01 Bone therapy recommended after index fracture -Referred for further clinical opinion(n) | Q4.01 Bone therapy recommended after index fracture - Referred for further clinical opinion (%) | Q4.01 Bone therapy recommended after index fracture -Don't know (n) | Q4.01 Bone therapy recommended after index fracture - Don't know (%) | Q4.01 Bone therapy recommended after index fracture -Missing (n) | Q4.01 Bone therapy recommended after index fracture - Missing (%) | Q4.01 Bone therapy recommended after index fracture - Alendronate (n) | Q4.01 Bone therapy recommended after index fracture - Alendronate (%) | Q4.01 Bone therapy recommended after index fracture - Risedronate (n) | Q4.01 Bone therapy recommended after index fracture - Risedronate (%) | Q4.01 Bone therapy recommended after index fracture - Ibandronate (n) | Q4.01 Bone therapy recommended after index fracture - Ibandronate (%) | Q4.01 Bone therapy recommended after index fracture - Raloxifene (n) | Q4.01 Bone therapy recommended after index fracture - Raloxifene (%) | Q4.01 Bone therapy recommended after index fracture - Teriparatide (n) | Q4.01 Bone therapy recommended after index fracture - Teriparatide (%) | Q4.01 Bone therapy recommended after index fracture - Strontium (n) | Q4.01 Bone therapy recommended after index fracture - Strontium (%) | Q4.01 Bone therapy recommended after index fracture - Denosumab (n) | Q4.01 Bone therapy recommended after index fracture - Denosumab (%) | Q4.01 Bone therapy recommended after index fracture - Zoledronate (n) | Q4.01 Bone therapy recommended after index fracture - Zoledronate (%) | Q4.01 Bone therapy recommended after index fracture - Other hormone therapies (n) | Q4.01 Bone therapy recommended after index fracture - Other hormone therapies (%) | Q4.01 Bone therapy recommended after index fracture - Activated vitamin D (n) | Q4.01 Bone therapy recommended after index fracture - Activated vitamin D (%) | Q4.01 Bone therapy recommended after index fracture - Total recommended bone therapy(n) | Q5.01 Falls risk assessment performed by FLS - Not done (n) | Q5.01 Falls risk assessment performed by FLS - Not done (%) | Q5.01 Falls risk assessment performed by FLS - Falls risk assessment done/referred/ recommended (n) | Q5.01 Falls risk assessment performed by FLS - Falls risk assessment done/referred/ recommended (%) | Q5.01 Falls risk assessment performed by FLS - Not recorded (n) | Q5.01 Falls risk assessment performed by FLS - Not recorded (%) | Q5.01 Falls risk assessment performed by FLS - Missing (n) | Q5.01 Falls risk assessment performed by FLS - Missing (%) | Total patient records (n) | Patients followed-up (of those prescribed bone therapy or referred for further clinical opinion or to GP) (n) | Patients followed-up (of those prescribed bone therapy or referred for further clinical opinion or to GP) (%) | Total recommended bone therapy (n) | Proportion of patients with a valid bone therapy recommendation, reported as starting treatment within 4 months of index fracture by FLS from January to June 2016 (n) | Proportion of patients with a valid bone therapy recommendation, reported as starting treatment within 4 months of index fracture by FLS from January to June 2016 (%) |
| Data field description | Name of participating hospital or Trust | How many cases each FLS has included | Whether or not data submitted by each FLS was uploaded in bulk or not | Number of fields out of 29 with 20% or more missing data submitted by each submitting FLS | Number of fields out of 29 with 50% or more missing data submitted by each submitting FLS | Estimated number of hip fracture patients (using NHFD data and rule of 5) | Estimated number of non-hip fracture patients (using NHFD data and rule of 4) | Number of hip fracture patients submitted to the FLS-DB | Number of non-hip patients submitted from FLS-DB | Percentage of estimated number of hip fragility fractures patients submitted | Percentage of estimated number of non-hip fragility fractures patients submitted | Number of patients assessed by the FLS within 7 days | Percentageof patients assessed by the FLS within 7 days | Number of patients assessed within 30 days | Percentage of patients assesed within 30 days | Number of patients assesed within 90 days | Percentage of patients assesed within 90 days | Number of patents where the diagnosis to FLS assessment was 91 days or more (n) | Percentage of patents where the diagnosis to FLS assessment was 91 days or more | Number of patients where diagnosis to FLS assessment could not be calculated | Percentage of patients where diagnosis to FLS assessment could not be calculated | Number of patients receiving a DXA scan within 7 days of fracture | Percentage of patients receiving a DXA scan within 7 days of fracture | Number of patients receiving a DXA scan within 30 days of fracture | Percentage of patients receiving a DXA scan within 30 days of fracture | Number of patients receiving a DXA scan within 90 days of fracture | Percentage of patients receiving a DXA scan within 90 days of fracture | Number of patients receiving a DXA scan at 91 days or more post fracture | Percentage of patients receiving a DXA scan at 91 days or more post fracture | Number of patients where diagnosis to DXA could not be calculated | Percentage of patients where diagnosis to DXA could not be calculated | Total number of those recommended a DXA scan | Number of patients recommended (oral bisphosphonates, denosumab, zolendronate) bone therapy recommended after index fracture | Percentage of patients recommended (oral bisphosphonates, denosumab, zolendronate) bone therapy recommended after index fracture | Number of cases where bone therapy was reported as inappropriate | Percentage of cases where bone therapy was reported as inappropriate | Number of cases where bone therapy was reported as informed decline | Percentage of cases where bone therapy was reported as informed decline | Number of patients who were referred to GP to decide prescription for bone therapy | Percentage of patients who were referred to GP to decide prescription for bone therapy | Number of patients who were referred for further clinical opinion for bone therapy | Percentage of patients who were referred for further clinical opinion for bone therapy | Number of cases where its is not known if patients were recommended bone therapy | Percentage of cases where its is not known if patients were recommended bone therapy | Number of cases where bone therapy reccommendation was missing | Percentage of cases where bone therapy reccommendation was missing | Number of patients recommended Alendronate | Percentage of patients recommended Alendronate | Number of patients recommended Risedronate | Percentage of patients recommended Risedronate | Number of patients recommended Ibandronate | Percentage of patients recommended Ibandronate | Number of patients recommended Raloxifene | Percentage of patients recommended Raloxifene | Number of patients recommended Teriparatide | Percentage of patients recommended Teriparatide | Number of patients recommended Strontium | Percentage of patients recommended Strontium | Number of patients recommended Denosumab | Percentage of patients recommended Denosumab | Number of patients recommended Zoledronate | Percentage of patients recommended Zoledronate | Number of patients recommended other hormone therapies | Percentage of patients recommended other hormone therapies | Number of patients recommended activated vitamin D | Percentage of patients recommended activated vitamin D | Total number of patients recommended bone therapy | Number of patients that did not have a falls risk assessment | Percentage of patients that did not have a falls risk assessment | Number of patients that had falls risk assessment done or referred to or recommended by a FLS | Percentage of patients that had falls risk assessment done or referred to or recommended by a FLS | Number of patients where the falls risk assessment was not recorded | Percentage of patients where the falls risk assessment was not recorded | Number of patients where the falls risk assessment was missing | Percentage of patients where the falls risk assessment was missing | Total records of patients prescribed anti-osteoporosis medication or referred for further clinical opinion or to GP | Number of patients followed up | Percentage of patients followed up | Number of patients recommended bone therapy | Number with a valid bone therapy recommendation, reported as starting treatment within 4 months of index fracture by FLS from January to June 2016 | Percentageof patients with a valid bone therapy recommendation, reported as starting treatment within 4 months of index fracture by FLS from January to June 2017 |
| Data field type | String | Integer | String | Integer | Integer | Integer | Integer | Integer | Integer | Percentage | Percentage | Integer | Percentage | Integer | Percentage | Integer | Percentage | Integer | Percentage | Integer | Percentage | Integer | Percentage | Integer | Percentage | Integer | Percentage | Integer | Percentage | Integer | Percentage | Integer | Integer | Percentage | Integer | Percentage | Integer | Percentage | Integer | Percentage | Integer | Percentage | Integer | Percentage | Integer | Percentage | Integer | Percentage | Integer | Percentage | Integer | Percentage | Integer | Percentage | Integer | Percentage | Integer | Percentage | Integer | Percentage | Integer | Percentage | Integer | Percentage | Integer | Percentage | Integer | Integer | Percentage | Integer | Percentage | Integer | Percentage | Integer | Percentage | Integer | Integer | Percentage | Integer | Integer | Percentage |
| Data field format | String | n | Y/N | n | n | n | n | n | n | n.n | n.n | n | n.n | n | n.n | n | n.n | n | n.n | n | n.n | n | n.n | n | n.n | n | n.n | n | n.n | n | n.n | n | n | n.n | n | n.n | n | n.n | n | n.n | n | n.n | n | n.n | n | n.n | n | n.n | n | n.n | n | n.n | n | n.n | n | n.n | n | n.n | n | n.n | n | n.n | n | n.n | n | n.n | n | n | n.n | n | n.n | n | n.n | n | n.n | n | n | n.n | n | n | n.n |